Thompson H J, Ronan A M, Ritacco K A, Meeker L D
Carcinogenesis. 1986 May;7(5):837-40. doi: 10.1093/carcin/7.5.837.
The effect of combined treatment with D,L-2-difluoromethylornithine (DFMO) and tamoxifen on the growth status, ornithine decarboxylase (ODC) activity and polyamine content of established 1-methyl-1-nitrosourea (MNU)-induced mammary tumors was investigated. DFMO treatment, a 0.125% solution provided as drinking water, inhibited the rate of tumor occurrence and reduced the number of mammary tumors induced by a high dose of MNU (50 mg/kg body weight) during the first 120 days post-carcinogen treatment. Tamoxifen was administered daily via s.c. injection (25 micrograms/100 g body weight) to tumor-bearing rats in both treatment groups, i.e. control and DFMO-treated, for a 30-day period beginning 120 days after carcinogen. Tamoxifen treatment induced tumor regression but the percentage of regressing, static or growing tumors was no different in the presence or absence of DFMO. Whereas the mammary tumors of DFMO-treated rats had reduced ODC activity and lower polyamine concentrations in comparison to the tumors of untreated animals, tamoxifen had no effect on these parameters independent of its effect on tumor growth status. DFMO did not increase the efficacy of tamoxifen in inducing tumor regression.
研究了D,L-2-二氟甲基鸟氨酸(DFMO)与他莫昔芬联合治疗对已建立的1-甲基-1-亚硝基脲(MNU)诱导的乳腺肿瘤的生长状态、鸟氨酸脱羧酶(ODC)活性和多胺含量的影响。DFMO治疗采用0.125%的溶液作为饮用水,在致癌物处理后的前120天内,抑制了高剂量MNU(50mg/kg体重)诱导的肿瘤发生率,并减少了乳腺肿瘤的数量。在两个治疗组(即对照组和DFMO治疗组)中,从致癌物处理后120天开始,对荷瘤大鼠每天通过皮下注射给予他莫昔芬(25微克/100克体重),持续30天。他莫昔芬治疗可诱导肿瘤消退,但无论是否存在DFMO,消退、静止或生长的肿瘤百分比均无差异。与未治疗动物的肿瘤相比,DFMO治疗的大鼠乳腺肿瘤的ODC活性降低,多胺浓度降低,而他莫昔芬对这些参数没有影响,与其对肿瘤生长状态的影响无关。DFMO并未提高他莫昔芬诱导肿瘤消退的疗效。